MAY 30, 2014 09:00 AM PDT

How does the soluble mechanistic biomarker 14-3-3 eta assist in the management of Rheumatoid Arthritis?

16 44 1805

  • Chief Scientific Officer, AugureX Life Sciences Corp
      Anthony serves as the Chief Scientific Officer at Augurex Life Sciences Corp, a company that he co-founded with CEO, Mrs. Norma Biln. Anthony's creativity and business acumen have set him apart from most scientific leaders. Anthony has worked in the life sciences space for 20 years and has consistently created progressive opportunities that have delivered great returns for companies that he has been involved with. He received his PhD from the Faculty of Medicine at the University of British Columbia in Vancouver, Canada.


    RA is a chronic autoimmune disease that if left untreated results in severe joint destruction. It is estimated that 30-50% of patients will end up on workplace disability within 5 years of diagnosis. Early identification of RA, assessment of the severity of disease at presentation, together with a prompt and effective treatment strategy can significantly improve a patient's prognosis. To enable all of this, new markers are required 1) to improve the diagnosis of RA; 2) to efficiently stratify patients into different risk categories and 3) to guide treatment decisions.

    The 14-3-3 family of proteins are ubiquitously expressed intracellular chaperonins. In 2007, Kilani et al. demonstrated that the eta isoform was abundantly expressed in the synovial fluid and serum of patients with RA. They also demonstrated that there was a significantly strong correlation with the levels of MMPs, and that extracellular 14-3-3η possesses ligand-like activity capable of inducing these degradative enzymes underscoring its role in the pathogenesis of joint damage in RA. Since 14-3-3 eta is not normally present extracellularly, the immune system sees soluble 14-3-3 eta as foreign. Using quantitative assays, we have reported that serum 14-3-3 eta and its auto-antibodies are highly specific RA markers which together identify greater than 90% of early RA patients. Patients who are 14-3-3 eta protein positive have worse disease outcomes over 5 years compared to the patients who are 14-3-3 eta negative. This is likely due to the role that 14-3-3 eta plays in inducing pro-inflammatory factors like TNF alpha that also perpetuate disease.

    Learning Objectives

    At the end of the presentation, participants will be able to:

    1. Understand the how markers are used in the management of RA and what are the current needs.
    2. Understand how the two 14-3-3 eta biomarkers assist with the management of RA

    Show Resources
    Loading Comments...